Evaluation of circulating sRAGE in osteoporosis according to BMI, adipokines and fracture risk: a pilot observational study
© The Author(s). 2017
Received: 25 January 2017
Accepted: 7 June 2017
Published: 14 June 2017
Osteoporosis is a systemic metabolic disease based on age-dependent imbalance between the rates of bone formation and bone resorption. Recent studies on the pathogenesis of this disease identified that bone remodelling impairment, at the base of osteoporotic bone fragility, could be related to protein glycation, in association to oxidative stress. The glycation reactions lead to the generation of glycation end products (AGEs) which, in turn, accumulates into bone, where they binds to the receptor for AGE (RAGE). The aim of this study is to investigate the potential role of circulating sRAGE in osteoporosis, in particular evaluating the correlation of sRAGE with the fracture risk, in association with bone mineral density, the fracture risk marker FGF23, and lipid metabolism.
Circulating level of soluble RAGE correlate with osteopenia and osteoporosis level. Serum sRAGE resulted clearly associated on the one hand to bone fragility and, on the other hand, with BMI and leptin. sRAGE is particularly informative because serum sRAGE is able to provide, as a single marker, information about both the aspects of osteoporotic disease, represented by bone fragility and lipid metabolism.
The measure serum level of sRAGE could have a potential diagnostic role in the monitoring of osteoporosis progression, in particular in the evaluation of fracture risk, starting from the prevention and screening stage, to the osteopenic level to osteoporosis.
KeywordsCirculating RAGE Glycation end products Osteoporosis Fracture risk
Osteoporosis is defined, according to 2001 NHI consensus conference, as a systemic disease characterized by loss of bone volume and resulting in a reduced skeletal integrity leading to a higher risk of bone fracture [1, 2]. Osteoporosis develops because of an age-dependent imbalance between the rates of bone formation and bone resorption  and is an emerging disease due to the increase of the population average age and its socioeconomic and public health impact is estimated to significantly increase in the next future. Due to the association with bone fragility and fracture risk, this disease interferes not only with the quality of life but also with life expectancy, in particular in elder people [4, 5] . The current recommendation for osteoporosis screening is the diagnosis by Bone Densitometry or DXA (Dual-energy X-ray absorptiometry) Scan, but even though this approach correlates with fracture risk and it can considered a good fracture predictor, many additional factors play a role in determining risk of fracture. While the first diagnosis of osteoporosis is based on bone mineral density (BMD), the evaluation of the individual fracture risk should consider all the clinical risk factors, ranging from age, sex, metabolic status and bone remodelling status [6, 7].
On the one hand, DXA scan gives the static measurement of bone density in specific bone sites, on the other hand, additional diagnostic tool, such as bone turnover biomarkers, reflects the dynamic changes of bone turnover in the whole skeletal [8–10]. Therefore, the comprehension of the biochemical mechanisms involved in the pathogenesis of osteoporosis could provide new diagnostic tool for improving the sensibility and specificity the prediction of fracture risk .
Osteoporosis is a systemic metabolic disease and recent studies on the pathogenesis of this disease identified that bone remodelling impairment, at the base of osteoporotic bone fragility, could be related to protein glycation, in association to oxidative stress . The glycation reactions lead to the generation of glycation end products (AGEs) which, in turn, accumulates into bone, where they binds to the receptor for AGE (RAGE) . The RAGE receptor belongs to the immunoglobulin superfamily of cell- surface molecules expressed in different cell types, including osteoclasts and osteoblasts. Upon binding AGEs, RAGE increase osteoclasts activity and decrease osteoblasts activity [12, 13], thus contributing to increase bone resorption and, ultimately, bone fragility [5, 14].
The negative action of AGEs-RAGE axis is compensated by the soluble form of RAGE receptor (sRAGE), which is a decoy receptor of AGEs . Being a soluble receptor, sRAGE binds AGEs but doesn’t lead to any signaling pathway, thus competing with the signaling, cell-bound RAGE receptor and, as a consequence, limiting the AGEs-RAGE axis action .
RAGE may be bound by many ligands which include advanced glycation endproducts (AGEs), certain mem-bers of the S100/calgranulin family, extracellular HMGB1-amphoterin, the integrin Mac-1, amyloid beta-peptide and amyloid fibrils. Acting as counter-receptor for leukocyte integrins RAGE may also have an important role in cell adhesion and clustering as well as recruitment of inflammatory cells [16, 17]. Other important ligands for RAGE may be glycosaminoglycans (including chondroitin sulfate, dermatan sulfate and heparan sulfate) which are frequently attached to proteoglycans on the surface of cancer cells and play an important role in the malignant transformation of the tumor and metastasis .
Being involved in the inflammatory response , RAGE ligand (s)/RAGE system, in particular the axes AGE-RAGE is involved in the pathogenesis of a variety of inflammatory disorders, ranging from diabetes to renal disease, sepsis and cardiovascular disease . In particular, the circulating soluble form of the RAGE receptor (sRAGE) has been recently described as a marker of disease in different pathologies, ranging from cardiovascular disease to acute liver failure  and metabolic disorder in obesity and diabetes [5, 20], but the diagnostic role of sRAGE in osteoporosis has not been described so far.
The aim of this study is to investigate the potential role of circulating sRAGE in osteoporosis, in particular evaluating the correlation of sRAGE with the fracture risk, in association with bone mineral density e and the fracture risk marker FGF23 (Fibroblast Growth Factor 23), involved in bone mineral metabolism. Since osteoporosis pathogenesis is strictly related with the metabolic status [21, 22], the aim of this study is also to evaluate the role of sRAGE as marker of osteoporosis in correlation with BMI and the adipokines leptin, adiponectin and visfatin.
The study involves 84 postmenopausal female volunteers (mean age 53 ± 6 years old) enrolled in the region of Lombardia and Calabria, as described in our previous work (Montalcini et al. 2015 ). All participants were evaluated for familiarity of osteoporosis and past fractures, medication use, physical exercise and smoke habits. Post menopausal status was defined as FSH level higher than 40 IU/l or one year at least of absence of natural mense.
Exclusion criteria were: presence of diabetes or any metabolic condition affecting bone metabolism (kidney, thyroid, rheumatic and hematological disease, malignant tumors) taking drug, hormone therapy or vitamin D affecting bone metabolism. The patients in our study was not under bisphosphonates therapy or other anti-osteoporotic therapy.
Written informed consent was obtained from all participants included in the study. All procedures followed were in accordance with the Helsinki of Declaration of 1975, as revised in 2000 and 2008 and it was approved by both the Ethic Committee ASL Milan 2 and The University Hospital Mater Domini, Catanzaro (Italy).
Trial registration number: 2631, name of registry: Comitato Etico indipendente della ASL Milano due. URL: http://www.aslm2.it, date of registration: September 19, 2011. Date of enrolment of the first participant 1 October 2011.
BMD evaluation of lumbar spine and left femoral was assessed by DXA (Horologic QDR Inc., MA. USA). BMD was expressed as T -score (number of standard deviation from healthy young mean) and Z- score (number of standard deviations from healthy women of the same age) calculated on the basis of physiological reference values. On the basis of T-score value the patients was classified as having normal bone (T-score > −1), osteopenia (Tscore: −1 to −2.49) or osteoporosis (T-score ≤ − 2.5).
In vivo precision, calculated as repeated measurements on 30 women, was <1%.
Body weight and BMI was measured as described in Montalcini et al. 2015 . Briefly, body weight was measured with a calibrated scale before breakfast subtracting the weight of clothes. Height was measured by wall- mounted stadiometer and BMI was calculated as weight (kg)/(height (m)) 2. According to BMI values, patients were classified as obese (BMI > 30), overweight (BMI 25–30) or normal weight (BMI < 25).
Glomerular filtration rate
Glomerular filtration rate was calculated for the whole population and for each RAGE quartile by CKD-EPI formula:
GFR = 141 * min(Scr/κ,1)α * max(Scr/κ, 1)-1.209 * 0.993Age * 1.018 [if female] * 1.159 [if black]Scr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is −0.329 for females and −0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1.
sRAGE, FGF23 and adipokines ELISA assay
Blood was sampled from all patients and sera were separated from whole blood after complete coagulation, by centrifugation at 3000 rpm for 10 min. Sera were stored at −70 °C until ELISA assay analyses.
Levels of soluble RAGE, C-Terminal FGF23, Leptin, Adiponectin and Visfatin in serum were determined by commercial assays, according to the manufacturers’ instructions (sRAGE: R&D Systems, Minneapolis, Minnesota, USA; C-Terminal FGF23: Imuunotopiscs, San Clemente, CA, USA; Leptin: Enzo Life Sciences, Farmingdale, New York, USA; Adiponectin and Visfatin: AdipoGen AG, Liestal, Switzerland).
For the sRAGE assay, the sensitivity was 4.44 pg/mL, and intra- and inter-assay coefficients of variation were 2.4% and 4.7%, respectively. For the FGF23 assay, the sensitivity was 1.5 RU /mL, and intra- and inter-assay coefficients of variation were2.4% and 4.7%, respectively. According to manufacturer (, Imuunotopiscs, San Clemente, CA, USA) 1RU roughly equates to 2 pg/mL. For the Leptin assay, the sensitivity was 23.4. pg/mL, and intra- and inter-assay coefficients of variation were 4.4% and 3.7%, respectively. For the Adiponectin assay, the sensitivity was 1 ng/mL, and intra- and inter-assay coefficients of variation were 3.3% and 2.75%, respectively. For the Visfatin assay, the sensitivity was 30.0 pg/mL, and intra- and inter-assay coefficients of variation were 2.3% and 4.6%, respectively.
For all parameters, the normality of distribution of the three groups was verified by KS (Kolmogorov-Smirnov) normality and results are reported as mean ± standard deviation (SD). Statistical analysis was done using one-way ANOVA, p < 0.05 being considered significant and p < 0.001 highly significant. The correlation of sRAGE with LBMD (lumbar bone mineral density) and FBMD (femoral bone mineral density) (expressed as T-score and Z-score) and with FGF23 was calculated as Spearman correlation (r) calculating the 95% confidence interval. All statistical analysis was performed using PRISM 3.0 software.
Glomerular filtration rate and sRAGE
Glomerular filtration rate was calculated by CKD-EPI formula for the whole population and for each RAGE quartile, in order to evaluate whether it could affect sRAGE levels in our patients . The mean eGFR calculated on the whole patient group was 88,71 ± 11,86 mL/min per 1.73 m2, while it resulted 85,05 ± 10,74, 89,45 ± 12,71, 88,91 ± 9,56, 84,85 ± 9,13 mL/min per 1.73 m2 in the first, second, third and fourth sRAGE quartiles, respectively. Therefore, no significative differences in eGFR were observed among sRAGe quartiles and compared to total mean eGFR.
sRAGE and bone mineral density
A total of 12 subject present osteoporosis, while 32 had osteopenia and 40 normal bone density values, as assessed by T-score and Z- score.
sRAGE and fracture risk
The Spearman correlation analysis (Panel C) did not find a strong correlation between serum FGF23 and the whole sRAGE values, while after the classification into sRAGE quartile an increasing correlation with serum FGF23 emerged, reaching high value in the third and even more in the fourth sRAGE quartile. These results indicates a correlation between sRAGE and fracture risck marker FGF23.
sRAGE and BMI
BMI and bone status
Figure 4 Panel a shows the mean FMBD and LBMD as Tscore and Z-score in three BMI group: normal (BMI < 25), overweight (BMI: 25–30) or obese (BMI > 30).Only in normal BMI group the mean lumbar T-score and femoral Z-score revealed a decrease of BMD but since the BMD values of the group are quite heterogeneous, Standard Deviation resulting in quite high. The percentage of normal bone, osteopenic and osteoporotic subject, according to lumbar (panel B) and femoral (panel C) T-score values, was evaluated into each BMI group. At the increase of BMI correspond a decrease of osteopenia and osteoporosis, and an increase of normal bone. In particular, according to femoral T-score, at BMI values over 30 there is a complete absence of osteoporotic subjects. These results indicates a decrease of osteopenia and osteoporosis according to BMI. Increase
sRAGE and Adipokines
Adiponectin and Visfatin (Fig. 5 panel a and b) displayed no significative differences among sRAGE quartiles, while Leptin and, as a consequence, Leptin/Adiponectin Ratio (Fig. 5 panel c and d) displayed a statistically significative decrease according to sRAGE quartiles.
Adiponectin and Visfatin display no significative correlation with total sRAGE or sRAGE quartiles, while Leptin and Leptin/Adiponectin Ratio displayed a good negative correlation (p < 0.001) with total sRAGE. This negative correlation increase according to sRAGE quartiles and it is particularly evident and significative (p < 0.001) n the forth quartile of sRAGE (panel E). These results indicates a negative correlation of sRAGE with leptin and Adiponectin.
Several evidences indicated that AGEs are involved in the pathogenesis of osteoporosis  and AGEs-RAGE interaction modulates osteoclasts and osteoblasts activity [24, 25]. For this reason we aimed to investigate the potential diagnostic role of soluble RAGE in osteoporosis. Our result clearly indicates that circulating level of soluble RAGE correlate with osteopenia and osteoporosis level (Fig. 1). This correlation is particularly evident by scoring RAGE into four quartiles.. These results clearly indicate that sRAGE correlates with disease progression from osteopenic to osteoporosis level. Usually sRAGE is reported to be high in healthy patients and lower in pathological condition, but this is not the first case where sRAGE, on the contrary, correlates with disease progression, behaving as a marker of disease progression. Indeed very recent evidenced that sRAGE, as widely described by Kailash Prasad , is not always a marker of good prognosis, because it can be reduced in some disease [27–30] and elevated in others [30–33]. The biological function of sRAGE is to bind circulating AGE, which could have detrimental effect on tissues, thus playing a protective role. For this reason in most of the cases, such as cardiovascular disorders, sRAGE, as a protective factor, is elevated in healthy subject and low in disease. On the contrary, in some cases such as diabetes renal disease, sRAGE is elevated compared to healthy controls as well as AGEs . Similarly, recent evidences indicates a high level of sRAGE is present in acute respiratory distress and bronchiolitis , idiopathic pulmonary fibrosis  and it can correlate with disease severity in lung transplantation  and long term hemodyalisis patients .
It is known that AGEs accumulates in bone tissue at increasing ages, because bone tissue is susceptible to aGE accumulation due to its turnover. During bone remodelling bone cells are in close proximity to to AGE-modified proteins, such as collagen Type I and its degradation products. Bone cells express RAGE and can directly interact with Age, regulating differentiation maturation and function. Therefore, protein glycation in clearly involved in age- regulating bone disorders . Franke et al. reported that on the one hand AGE-RAGE binding activates inflammatory response by inducing NFkB and TNF-α, on the other hand NFkB upregulates RAGE expression, thereby activating a self-promoting cicle among RAGE, Age and inflammatory mediators . AGEs induced a decrease of osteoblast proliferation and osteoblast apoptosis . In addition circulating AGE are reported to decrease bone strength . The circulating sRAGE is the direct effect of the proteolitic cleavage of RAGE by metalloproteinases, and recent evidences suggested that diseases characterized by high level of MMPs, such as diabetes and renal disease [40, 41] display high level of serum sRAGE compared to healthy controls. Osteoporosis is characterized by a high expression of MMPs, acting on bone matrix resorption, and this can be the reason of high level of serum sRAGE in osteoporosis level. Therefore, circulating levels of sRAGE can be considered a direct indicator of circulating AGEs and, therefore, bone resorption status.
Consistently with this, our data indicates that serum sRAGE correlates with bone density decrease, ranging from the level of osteopenia to marked osteoporosis, confirming a correlation of serum sRAGE with the stage of bone fragility. This is also confirmed by the correlation of sRAGE quartiles with a strong marker of bone fracture risk, FGF23, as shown in Fig. 2. Being an important regulator of vitamin D and phosphorus, a key process in bone matrix turnover, Fibroblast growth factor-23 (FGF23) is considered a strong marker of bone fracture [42, 43]. In our patients there if we consider the whole population there is not a strong correlation of FGF23 and total fracture risk, as reported by Montalcini et Al, 2015 . If we consider the classification according to T-score into normal bone, osteopenic and osteoporotic patients, a slightly increasing concentration of FGF23 results in osteopenic and osteoporotic group. In particular the only significative difference is observed in osteoporotic patients, displaying higher bone fragility, while at the level of osteopenia the risk of fracture is still too low to induce a marked and significative increase of FGF23. In consistence with that, there is a strong significative increase of FGF23 according to sRAGE quartiles, with a significative increase in particular in the third and even more in the highest quartile of sRAGE, suggesting a correlation of sRAGE with the increasing risk of bone fracture. This is also confirmed by the correlation analysis between serum FGF23 and sRAGE quartiles: even if the correlation with total sRAGE is not so strong, considering sRAGE quartiles classification a strong positive correlation emerges in the third and fourth quartiles. All these results clearly indicate that sRAGE can be considered a new biomarker of fracture risk in the osteoporosis.
It is well established that bone fracture risk is influenced not only by bone density but also by several metabolic factors, such as BMI and lipid metabolism [21, 22]. For this reason, we evaluated the association of BMI with the level of serum sRAGE. We observed a decrease of BMI according to sRAGE quartiles, and in particular if we categorize the patients into each sRAGE quartile according to the BMI standard classification (BMI < 25: normal weight, BMI 25–30 overweight, BMI > 30 obese) we observe a sticking prevalence of normal weight subject in the highest quartile of sRAGE. Accordingly, no obese subject is present in the highest quartile of sRAGE while the highest prevalence of obese subject results in the lowest quartile of sRAGE. This data indicate that there is a negative correlation with sRAGE and BMI.
Taken together these results indicates that s RAGE display a strong negative correlation with leptin and LAR ratio.
This is the first study to our knowledge evaluating serum sRAGE in normal, osteopenic and osteoporotic patients. The limit of the study is to evaluate only few of the great number of parameter in the global evaluation of bone and lipid metabolism in fracture risk. This is pilot study evaluating the association of sRAGE and bone fragility in osteoporosis, and further investigation could be performed on a wider panel of parameter. The study is performed on a selected population of a small number of patients, all belonging to female gender and recruited into a local area, but since osteoporosis affects also male, further investigation could be performed on both genders, in order to replicate and extend the analysis.
This marker resulted clearly associated on the one hand to bone fragility and, on the other hand, with BMI and leptin. Since the ultimate goal of osteoporosis diagnosis and monitoring is the evaluation of fracture risk, it is important to take into account all the aspect affecting bone fragility. In this context sRAGE is particularly informative because serum sRAGE is able to provide, as a single marker, information about both the aspects of osteoporotic disease, represented by bone fragility and lipid metabolism.
The exact mechanism connecting AGEs and bone fragility is still unclear, but the level of advanced glycation end products (AGEs) have been recently reported to be inversely correlated with bone toughness and rigidity, due to their role in the inhibition of the synthesis of type I collagen, [39, 50, 51]. In addition, it is known that obesity is connected with increased amounts of AGE in the body [52, 53], leading to decreased bone toughness. In this context, our results shows that sRAGE would play a role in regulating AGEs, also according to lipid metabolism.
The measure serum level of sRAGE could have a potential diagnostic role in the monitoring of osteoporosis progression, in particular in the evaluation of fracture risk, starting from the prevention and screening stage, to the osteopenic level to osteoporosis.
We acknowledge Fondazione di Piacenza eVigevano.for supporting this research.
The study was supported by Fondazione di Piacenza eVigevano.
Availability of data and materials
The datasets analyzed during the current study are available from the corresponding author on reasonable request.
EG and MMCR: study design, data analysis, article drafting; MG M ELISA Assay; CG, PG., AC,, TM, AP: patients recruitment DXA, antropometric measurements. All authors read and approved the final manuscript.
The authors declare they have no competing interests.
Consent for publication
The study was approved by the institutional review committee of the participating hospitals (Ethic Committee ASL Milan 2 and The University Hospital Mater Domini, Catanzaro, Italy) and all participants gave written informed consent.
Ethics approval and consent to participate
Informed consent was obtained from all participants included in the study. All procedures followed were in accordance with the Helsinki of Declaration of 1975, as revised in 2000 and 2008 and it was approved by both the Ethic Committee ASL Milan 2 and The University Hospital Mater Domini, Catanzaro (Italy). The authors declare that the study was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest, and that they gave their consent for publication. No patient identifiers are used in published abstracts and manuscripts.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Hein GE. Glycation endproducts in osteoporosis--is there a pathophysiologic importance? Clin Chim Acta. 2006;371:32–6.View ArticlePubMedGoogle Scholar
- Cockey CD. Coming to consensus on osteoporosis. AWHONN Lifelines. 2000;4:21.View ArticlePubMedGoogle Scholar
- Mohan S, Farley JR, Baylink DJ. Age-related changes in IGFBP-4 and IGFBP-5 levels in human serum and bone: implications for bone loss with aging. Prog Growth Factor Res. 1995;6:465–73.View ArticlePubMedGoogle Scholar
- Parsons LC. Osteoporosis: incidence, prevention, and treatment of the silent killer. Nurs Clin North Am. 2005;40:119–33.View ArticlePubMedGoogle Scholar
- Yamagishi S, Nakamura K, Inoue H. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients. Med Hypotheses. 2005;65:1013–5.View ArticlePubMedGoogle Scholar
- Camacho PM, Lopez NA. Use of biochemical markers of bone turnover in the management of postmenopausal osteoporosis. Clin Chem Lab Med. 2008;46:1345–57.View ArticlePubMedGoogle Scholar
- Vasikaran SD. Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis. Crit Rev Clin Lab Sci. 2008;45:221–58.View ArticlePubMedGoogle Scholar
- Tamaki J, Iki M, Kadowaki E, et al. Biochemical markers for bone turnover predict risk of vertebral fractures in postmenopausal women over 10 years: the Japanese population-based osteoporosis (JPOS) cohort study. Osteoporos Int. 2013;24(3):887–97. doi:10.1007/s00198-012-2106-7.View ArticlePubMedGoogle Scholar
- Biver E, Chopin F, Coiffier G, et al. Bone turnover markers for osteoporotic status assessment? A systematic review of their diagnosis value at baseline in osteoporosis. Joint Bone Spine. 2013;79:20–5.Google Scholar
- Chopin F, Biver E, Funck-Brentano T, et al. Prognostic interest of bone turnover markers in the management of postmenopausal osteoporosis. Joint Bone Spine. 2012;79(1):20–5. doi:10.1016/j.jbspin.2011.05.003.1.View ArticlePubMedGoogle Scholar
- Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 2000;1498:99–111.View ArticlePubMedGoogle Scholar
- Tanaka K, Yamaguchi T, Kaji H, Kanazawa I, Sugimoto T. Advanced glycation end products suppress osteoblastic differentiation of stromal cells by activating endoplasmic reticulum stress. Biochem Biophys Res Commun. 2013;438(3):463–7. doi:10.1016/j.bbrc.2013.07.126.View ArticlePubMedGoogle Scholar
- Okazaki K, Yamaguchi T, Tanaka K, et al. Advanced glycation end products (AGEs), but not high glucose, inhibit the osteoblastic differentiation of mouse stromal ST2 cells through the suppression of osterix expression, and inhibit cell growth and increasing cell apoptosis. Endocrinology. 2014;155(7):2402–10. doi:10.1210/en.2013-1818.View ArticlePubMedGoogle Scholar
- Willett TL, Pasquale J, Grynpas MD. Collagen modifications in postmenopausal osteoporosis: advanced glycation endproducts may affect bone volume, structure and quality. Curr Osteoporos Rep. 2014;12(3):329–37. doi:10.1007/s11914-014-0214-3.View ArticlePubMedGoogle Scholar
- Sanguineti R, Puddu A, Mach F, Montecucco F, Viviani GL. Advanced glycation end products play adverse proinflammatory activities in osteoporosis. Mediators Inflamm. 2014;2014:975872. doi:10.1155/2014/975872.
- Fritz G. RAGE: a single receptor fits multiple ligands. Trends Biochem Sci. 2011;36(12):625–32. doi:10.1016/j.tibs.2011.08.008.View ArticlePubMedGoogle Scholar
- Tesarova P, Kalousova M, Zima T, Tesar V. HMGB1, S100 proteins and other RAGE ligands in cancer - markers, mediators and putative therapeutic targets. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160(1):1–10. doi:10.5507/bp.2016.003.PubMedGoogle Scholar
- Balistreri CR, Candore G, Accardi G, Colonna-Romano G, Lio D. NF-kappaB pathway activators as potential ageing biomarkers: targets for new therapeutic strategies. Immun Ageing 2013 20;10(1):24. doi: 10.1186/1742-4933-10-24.
- Santilli F, Blardi P, Scapellato C, et al. Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and/or metabolic syndrome. Vasc Pharmacol. 2015;72:16–24. doi:10.1016/j.vph.2015.04.004.View ArticleGoogle Scholar
- Yang ZK, Shen Y, Shen WF, et al. Elevated glycated albumin and reduced endogenous secretory receptor for advanced glycation endproducts levels in serum predict major adverse cardio-cerebral events in patients with type 2 diabetes and stable coronary artery disease. Int J Cardiol. 2015;15(197):241–7. doi:10.1016/j.ijcard.2015.06.003.View ArticleGoogle Scholar
- Cao JJ. Effects of obesity on bone metabolism. J Orthop Surg Res. 2011;15(6):30. doi:10.1186/1749-799X-6-30.View ArticleGoogle Scholar
- Sharma S, Tandon VR, Mahajan S, Mahajan V, Mahajan A. Obesity: friend or foe for osteoporosis. J Midlife Health. 2014;5(1):6–9. doi:10.4103/0976-7800.127782.PubMedPubMed CentralGoogle Scholar
- Montalcini T, Gallotti P, Coppola A, et al. Association between low C-peptide and low lumbar bone mineral density in postmenopausal women without diabetes. Osteoporos Int. 2015;26(5):1639–46. doi:10.1007/s00198-015-3040-2.View ArticlePubMedPubMed CentralGoogle Scholar
- Hein G, Wiegand R, Lehmann G, Stein G, Franke S. Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology (Oxford). 2003;42:1242–6.View ArticleGoogle Scholar
- Kume S, Kato S, Yamagishi S, et al. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res. 2005;20:1647–58.View ArticlePubMedGoogle Scholar
- Prasad K. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality. Int J Angiol. 2014;23(1):11–6. doi:10.1055/s-0033-1363423.View ArticlePubMedPubMed CentralGoogle Scholar
- Selvin E, Halushka MK, Rawlings AM, et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes. 2013;62(6):2116–21. doi:10.2337/db12-1528.View ArticlePubMedPubMed CentralGoogle Scholar
- Hudson BI, Moon YP, Kalea AZ, et al. Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the northern Manhattan study (NOMAS). Atherosclerosis. 2011;216(1):192–8. doi:10.1016/j.atherosclerosis.2011.01.024.View ArticlePubMedPubMed CentralGoogle Scholar
- Miniati M, Monti S, Basta G, Cocci F, Fornai E, Bottai M. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respir Res. 2011;30(12):37. doi:10.1186/1465-9921-12-37.View ArticleGoogle Scholar
- Geroldi D, Falcone C, Emanuele E, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens. 2005;23:1725–9.View ArticlePubMedGoogle Scholar
- Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudeux JL. Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin Chem. 2005;51:1749–50.View ArticlePubMedGoogle Scholar
- Nin JW, Jorsal A, Ferreira I, et al. Higher plasma soluble receptor for advanced Glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes. 2010;59(8):2027–32. doi:10.2337/db09-1509.View ArticlePubMedPubMed CentralGoogle Scholar
- Fujisawa K, Katakami N, Kaneto H, et al. Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. Atherosclerosis. 2013;227(2):425–8. doi:10.1016/j.atherosclerosis.2013.01.016.View ArticlePubMedGoogle Scholar
- Rozycki HJ, Bradley J, Karam S. sRAGE is elevated in the lungs of premature infants receiving mechanical ventilation. Am J Perinatol. 2017;20 doi:10.1055/s-0037-1601311.
- Manichaikul A, Sun L, Borczuk AC, et al. Plasma soluble receptor for advanced Glycation Endproducts in idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2017; doi:10.1513/AnnalsATS.201606-485OC.
- Jung ES, Chung W, Kim AJ, et al. Associations between soluble receptor for advanced Glycation end products (sRAGE) and S100A12 (EN-RAGE) with mortality in long-term Hemodialysis patients. J Korean Med Sci. 2017;32(1):54–9. doi:10.3346/jkms.2017.32.1.54.View ArticlePubMedGoogle Scholar
- Franke S, Ruster C, Pester J, Hofmann G, Oelzner P, Wolf G. Advanced glycation end products affect growth and function of osteoblasts. Clin Exp Rheumatol. 2011;29(4):650–60.PubMedGoogle Scholar
- Alikhani M, Alikhani Z, Boyd C, et al. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone. 2007;40:345–53.View ArticlePubMedGoogle Scholar
- Yang DH, Chiang TI, Chang IC, Lin FH, Wei CC, Cheng YW. Increased levels of circulating advanced glycation end-products in menopausal women with osteoporosis. Int J Med Sci. 2014;11(5):453–60. doi:10.7150/ijms.8172.View ArticlePubMedPubMed CentralGoogle Scholar
- Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res. 2003;23:129–34.PubMedGoogle Scholar
- Hagen I, Schulte DM, Muller N, et al. Soluble receptor for advanced glycation end products as a potential biomarker to predict weight loss and improvement of insulin sensitivity by a very low calorie diet of obese human subjects. Cytokine. 2015;73(2):265–9. doi:10.1016/j.cyto.2015.02.022.View ArticlePubMedGoogle Scholar
- Jovanovich A, Buzkova P, Chonchol M, et al. Fibroblast growth factor 23, bone mineral density, and risk of hip fracture among older adults: the cardiovascular health study. J Clin Endocrinol Metab. 2013;98(8):3323–31. doi:10.1210/jc.2013-1152.View ArticlePubMedPubMed CentralGoogle Scholar
- Lane NE, Parimi N, Corr M, et al. Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: the osteoporotic fractures in men (MrOS) study. J Bone Miner Res. 2013;28(11):2325–32. doi:10.1002/jbmr.1985.View ArticlePubMedPubMed CentralGoogle Scholar
- Heidari B, Hosseini R, Javadian Y, Bijani A, Sateri MH, Nouroddini HG. Factors affecting bone mineral density in postmenopausal women. Arch Osteoporos. 2015;10:15. doi:10.1007/s11657-015-0217-4.View ArticlePubMedGoogle Scholar
- Jiang Y, Zhang Y, Jin M, Gu Z, Pei Y, Meng P. Aged-related changes in body composition and association between body composition with bone mass density by body mass index in Chinese Han men over 50-year-old. PLoS One. 2015;10(6):e0130400. doi:10.1371/journal.pone.0130400.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang J, Jin Y, Xu S, et al. Associations of fat mass and fat distribution with bone mineral density in Chinese obese population. J Clin Densitom. 2015;18(1):44–9. doi:10.1016/j.jocd.2014.03.001.View ArticlePubMedGoogle Scholar
- Tohidi M, Akbarzadeh S, Larijani B, et al. Omentin-1, visfatin and adiponectin levels in relation to bone mineral density in Iranian postmenopausal women. Bone. 2012;51(5):876–81. doi:10.1016/j.bone.2012.08.117.View ArticlePubMedGoogle Scholar
- Mohiti-Ardekani J, Soleymani-Salehabadi H, Owlia MB, Mohiti A. Relationships between serum adipocyte hormones (adiponectin, leptin, resistin), bone mineral density and bone metabolic markers in osteoporosis patients. J Bone Miner Metab. 2014;32(4):400–4. doi:10.1007/s00774-013-0511-4.View ArticlePubMedGoogle Scholar
- Lopez-Jaramillo P, Gomez-Arbelaez D, Lopez-Lopez J, et al. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Investig. 2014;18(1):37–45. doi:10.1515/hmbci-2013-0053.PubMedGoogle Scholar
- Roy B, Curtis ME, Fears LS, Nahashon SN, Fentress HM. Molecular mechanisms of obesity-induced osteoporosis and muscle atrophy. Front Physiol. 2016;29(7):439.Google Scholar
- Roy B. Biomolecular basis of the role of diabetes mellitus in osteoporosis and bone fractures. World J Diabetes 2013 15;4(4):101-113. doi: 10.4239/wjd.v4.i4.101.
- Unoki-Kubota H, Yamagishi S, Takeuchi M, Bujo H, Saito Y. Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice. Protein Pept Lett. 2010;17(9):1177–81.View ArticlePubMedGoogle Scholar
- de Andrade IS, Zemdegs JC, de Souza AP, et al. Diet-induced obesity impairs hypothalamic glucose sensing but not glucose hypothalamic extracellular levels, as measured by microdialysis. Nutr Diabetes. 2015;15(5):e162. doi:10.1038/nutd.2015.12.View ArticleGoogle Scholar